Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
Clinical trial NCT04708041 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04708041
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-15
- Primary completion
- 2029-10-23
- Enrollment
- 700
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.